Collectively, these data underscore the functional intersection between XPO1 activity and EGFR-driven signaling, supporting the relevance of XPO1 as a modulator of both primary and acquired resistance in EGFR-mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.